Australia markets closed

Abbott Laboratories (ABT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
126.72+1.67 (+1.34%)
At close: 4:02PM EDT
126.10 -0.62 (-0.49%)
After hours: 06:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close125.05
Open125.51
Bid126.72 x 800
Ask126.68 x 1200
Day's range124.88 - 126.84
52-week range103.13 - 129.70
Volume4,874,988
Avg. volume4,665,938
Market cap224.652B
Beta (5Y monthly)0.67
PE ratio (TTM)31.44
EPS (TTM)4.03
Earnings date20 Oct 2021
Forward dividend & yield1.80 (1.44%)
Ex-dividend date14 Oct 2021
1y target est137.05
  • Motley Fool

    3 Things Investors Should Love About Abbott's Q3 Results

    Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Abbott provided its third-quarter update before the market opened on Wednesday. Here are three things that investors should love about the healthcare-giant's Q3 results.

  • Motley Fool

    Why Abbott Laboratories Shot Higher Today

    Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. For the quarter, Abbott posted year-over-year sales growth of 23%, as its top line landed at $10.9 billion. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93.

  • Motley Fool

    Abbott Laboratories (ABT) Q3 2021 Earnings Call Transcript

    With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. With me today are Robert Ford, President and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer.